Chemotherapy-Induced Hair LossChemotherapy-Induced Hair Loss
Chemotherapy-Induced Hair Loss
Chemotherapy-Induced Hair Loss
患病率: Affects 65-85% of chemotherapy patients depending on regimen
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'haircited.com';
const params = 'condition\u003Dchemotherapy\u002Dhair\u002Dloss';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
About
Rapid, diffuse hair loss (anagen effluvium) caused by cytotoxic chemotherapy agents that target rapidly dividing cells, including hair matrix keratinocytes. Hair typically regrows after treatment completion, though texture and color may change.
Common Symptoms
Rapid diffuse shedding
Complete scalp hair loss
Eyebrow and eyelash loss
Body hair loss
Risk Factors
- Taxane chemotherapy
- Anthracycline chemotherapy
- Combination regimens
- Higher doses
Frequently Asked Questions
How is the evidence for Chemotherapy-Induced Hair Loss supplements graded?
We grade supplements on an A-F scale based on clinical study quality, consistency of results, sample sizes, and study design. Grade A indicates strong evidence from multiple clinical trials, while Grade D indicates preliminary evidence requiring further research.
What are common symptoms of Chemotherapy-Induced Hair Loss?
Common symptoms associated with Chemotherapy-Induced Hair Loss include Rapid diffuse shedding, Complete scalp hair loss, Eyebrow and eyelash loss, Body hair loss. If you are experiencing these symptoms, consult a healthcare professional for proper diagnosis and treatment options.
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。